Sign in
IMDX Stock Price, Chart, Stats & News
Insight Molecular Diagnostics Inc.
Save
Insight Molecular Diagnostics Inc. (IMDX) does not currently pay a dividend.
158.36M
Market cap
–
Current P/E
–
Forward P/E
IMDX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 56.67% |
Operating margin | -754.08% |
Pretax margin | -1238.52% |
Net margin | -1238.52% |
Effective tax rate | – |
ROA | -194.99% |
ROE | 684.60% |
D/E | -0.11x |
Interest coverage ratio | -280.53x |
IMDX valuation
P/E | – |
P/S | 23.56x |
P/B | -3.45x |
P/CF | -4.89x |
P/FCF | -4.00x |
P/OCF | -4.89x |
PEG | -0.05x |
EV multiple | -2.12x |
About
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis.
Similar securities
Based on sector and market capitalization
Report issue